Phase 2 Study – Bimiralisib in HNSCC recruiting now

Open-label, single arm, two-stage study, evaluating the efficacy and safety of bimiralisib in patients with recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) harboring NOTCH1 loss of function (LOF) mutations

Click here for Details